These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29172873)

  • 1. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
    Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
    J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
    Harper A; Blackwood L
    J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009-2013.
    Olmsted GA; Farrelly J; Post GS; Smith J
    J Feline Med Surg; 2017 Jun; 19(6):568-575. PubMed ID: 26951557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
    Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
    J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
    Merrick CH; Pierro J; Schleis SE; Sones EA; Wright ZM; Regan RC; Siedlecki CT; Bergman PJ
    Vet Comp Oncol; 2017 Sep; 15(3):710-717. PubMed ID: 27041701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate.
    Williams K; MacDonald-Dickinson V; Matsuyama A
    J Feline Med Surg; 2024 Sep; 26(9):1098612X241266418. PubMed ID: 39287178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy and safety of toceranib phosphate in cats with macroscopic mammary adenocarcinoma.
    Del Portillo Miguel I; Blackwood L; Maiques E; Pérez Roger I; Poch Jiménez E; Borrego J
    J Feline Med Surg; 2024 Aug; 26(8):1098612X241256473. PubMed ID: 39212426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
    Rosario CO; Musser ML; Yuan L; Mochel JP; Talbott J; Johannes CM; Berger EP
    Can Vet J; 2023 Dec; 64(12):1143-1148. PubMed ID: 38046430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Chon E; McCartan L; Kubicek LN; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
    Hicks KA; Leeper HJ; Curran KM
    Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.
    Holtermann N; Kiupel M; Hirschberger J
    Vet Comp Oncol; 2017 Jun; 15(2):632-640. PubMed ID: 26762970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
    Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of feline mast cell tumour with intertumoral heterogeneity: Identification of secondary mutations c.998G>C and c.2383G>C in KIT after resistance to toceranib.
    Tani H; Hifumi T; Ito K; Kuramoto T; Miyoshi N; Fujiki M; Nakayama T
    Vet Med Sci; 2024 Sep; 10(5):e70003. PubMed ID: 39177283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
    Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
    Pan X; Tsimbas K; Kurzman ID; Vail DM
    Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.